Evidence map›Paper›PMID 35743299›Full record

ArticleInternational journal of molecular sciences2022

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.

Esther Martínez-Martínez, Paola Atzei, Christine Vionnet, Carole Roubaty, Stephanie Kaeser-Pebernard, Reto Naef, Jörn Dengjel

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Esther Martínez-MartínezDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0003-1016-209X
Paola AtzeiTopadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren, Switzerland.
Christine VionnetDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.
Carole RoubatyDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.
Stephanie Kaeser-PebernardDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0002-6035-6979
Reto NaefTopadur Pharma AG, Grabenstrasse 11A, 8952 Schlieren, Switzerland.
Jörn DengjelDepartment of Biology, University of Fribourg, 1700 Fribourg, Switzerland.ORCID 0000-0002-9453-4614
University of Fribourg · CHTillotts Pharma (Switzerland) · CH

Funding

Innosuisse - Swiss Innovation Agency 29588.1 IP-LSUniversity of Fribourg Forschungspool
6 · The paper itself

Abstract

Wound healing pathologies are an increasing problem in ageing societies. Chronic, non-healing wounds, which cause high morbidity and severely reduce the quality of life of affected individuals, are frequently observed in aged individuals and people suffering from diseases affected by the Western lifestyle, such as diabetes. Causal treatments that support proper wound healing are still scarce. Here, we performed expression proteomics to study the effects of the small molecule TOP-N53 on primary human skin fibroblasts and keratinocytes. TOP-N53 is a dual-acting nitric oxide donor and phosphodiesterase-5 inhibitor increasing cGMP levels to support proper wound healing. In contrast to keratinocytes, which did not exhibit global proteome alterations, TOP-N53 had profound effects on the proteome of skin fibroblasts. In fibroblasts, TOP-N53 activated the cytoprotective, lysosomal degradation pathway autophagy and induced the expression of the selective autophagy receptor p62/SQSTM1. Thus, activation of autophagy might in part be responsible for beneficial effects of TOP-N53.

Indexed as

Nitric Oxide DonorsPhosphodiesterase 5 InhibitorsAgedAutophagyFibroblastsHumansKeratinocytesNitric OxideProteomeQuality of LifeSkinNitric OxideNitric Oxide DonorsPhosphodiesterase 5 InhibitorsProteomeautophagycGMPfibroblastsmass spectrometrynitric oxideNOproteomicssildenafilskinwound healing

Identifiers

PMID35743299
PMCPMC9224465
OpenAlexW4283210903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.